Sanofi SA · EURONEXT:SAN
Sanofi SA — Corporate Update (March 2017)
15 slides from Sanofi SA's corporate update, Mar 28, 2017
Slide 1: DUPIXENT FDA Approval Call
DUPIXENT® FDA Approval Call March 28, 2017 1
Slide 2: Sanofi Forward Looking Statements
Sanofi Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and thei
Slide 3: Regeneron Forward Looking Statements
Regeneron Forward Looking Statements This presentation includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially f
Slide 4: Agenda
Agenda Opening remarks – DUPIXENT®, a breakthrough innovation ● Olivier Brandicourt – Chief Executive Officer, Sanofi ● Leonard S. Schleifer, MD, PhD – Founder, President and Chief Executive Officer, Regeneron Q&A Session ● George D. Yancopoulos, MD, PhD – Founding Scientist, President and Chief Sci
Slide 5: DUPIXENT: A Breakthrough Treatment for Moderate-to-Severe Atopic Dermatitis (AD)
DUPIXENT®: A Breakthrough Treatment for Moderate-to- Severe Atopic Dermatitis (AD) ● A key new product launch for Regeneron and Sanofi ● Important addition to Sanofi Genzyme specialty care business ● Science driving innovation: First biologic therapy for AD approved in the US ● Excited to bring prod
Slide 6: IL-4/IL-13 Considered Common Drivers in the Following Diseases
Il-4/IL-13 Considered Common Drivers in the Following Diseases(1) Atopic Dermatitis Il-4/IL-13 signaling is considered to be Eosinophilic IL-4/ Asthma central to many Type-2 Esophagitis IL-13 mediated allergic diseases Nasal Polyps (1) Dupilumab is under clinical development in asthma, nasal polyps
Slide 7: AD is a Chronic, Inflammatory Skin Disease, Characterized by Intractable Pruritus
AD is a Chronic, Inflammatory Skin Disease, Characterized by Intractable Pruritus ● Moderate-to-severe form of AD can be a debilitating, life-altering condition that impacts people’s day-to-day functioning ● Characterized by intense itching and recurrent eczematous lesions ● Multifactorial etiology
Slide 8: DUPIXENT: The First FDA Approved Biologic for Adults with Uncontrolled Moderate-to-Severe AD
DUPIXENT®: The First FDA Approved Biologic for Adults with Uncontrolled Moderate-to-Severe AD DUPIXENT® INDICATIONS AND USAGE DUPIXENT® is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription ther
Slide 9: U.S. Launch Focused on Patients with the Highest Unmet Medical Need
U.S. Launch Focused on Patients with the Highest Unmet Medical Need IGA 4 IGA 1 Patient Focus at Launch Moderate-to-severe AD patients intolerant to or inadequate response to an existing therapy (Topical prescription therapies and Oral/systemic steroids or Immuno-suppressants) ● BSA affected: 86.5%
Slide 10: Target Physicians who Treat AD Patients and Have Experience Prescribing Biologics
Target Physicians who Treat AD Patients and Have Experience Prescribing Biologics Physician Focus at Launch Dermatologists (i.e. Psoriasis) Allergists/Immunologists Up to 7,000 doctors in the U.S. 10
Slide 11: A Commitment to Responsible Pricing: Valuing a Breakthrough Therapy for Moderate-to-Severe AD
A Commitment to Responsible Pricing: Valuing a Breakthrough Therapy for Moderate-to-Severe AD Clinical & Qualitative measures QoL Benefit Quantitative measures Breakthrough, Disease Burden/Treatment First-in-Class Therapy Landscape RESPONSIBLE Ensuring Continued PRICING FOR Cost-Effectiveness Invest
Slide 12: DUPIXENT WAC is Lower than Biologics Used to Treat Psoriasis
DUPIXENT® WAC is Lower than Biologics Used to Treat Psoriasis(1) AD is at Least as Burdensome a Yet DUPIXENT® WAC is Disease as Psoriasis(1) Lower than Psoriasis Biologics(2,3) (in USD) $90,000 30 $80,000 ~$83,000 Baseline Mean DLQI Score 25 $70,000 $60,000 20 14.5 - 16 $50,000 ~$41,000 15 11.5 - 13
Slide 13: Working Alongside Payers to Provide Appropriate Access For Patients
Working Alongside Payers to Provide Appropriate Access For Patients Payer Discussions Provide Patient Access ● Consultation with PBMs Aligned view on the burden of disease, the unmet need that exists and the right patient for treatment ● Early Formulary Coverage Expected(1) for a large population of
Slide 14: Comprehensive Support to Optimize Patient Access and Minimize Barriers to Treatment
Comprehensive Support to Optimize Patient Access and Minimize Barriers to Treatment Patient Support & Coverage Patient Access ● Education and personalized ● $0 Copay nurse support Program for eligible patients ● Benefits Investigation ● Patient ● Prior Authorization Assistance Assistance Program ● A
Slide 15: Q&A
Q&A DUPIXENT2> (dupilumab) p SANOFl eg REGENERON